KalVista Pharmaceuticals, Inc. (KALV)
Jun 11, 2026 - KALV was delisted (reason: acquired by Chiesi Group)
27.00
+0.01 (0.04%)
Inactive · Last trade price on Jun 10, 2026
KalVista Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for KalVista Pharmaceuticals stock had an average target of $28.6, with a low estimate of $27 and a high estimate of $35.
Price Target: $28.6 (+5.93%)
Analyst Consensus: Hold
Price Target
Chart* Price targets were last updated on May 7, 2026.
Analyst Ratings
The average analyst rating for KalVista Pharmaceuticals stock from 7 stock analysts was "Hold". This means that analysts believed this stock was likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 3 | 1 |
| Buy | 2 | 2 | 2 | 2 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 4 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Hold Maintains n/a | Hold | Maintains | n/a | n/a | May 15, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Hold Downgrades $42 → $27 | Hold | Downgrades | $42 → $27 | n/a | May 7, 2026 |
| H.C. Wainwright | H.C. Wainwright | Hold Downgrades $37 → $27 | Hold | Downgrades | $37 → $27 | n/a | May 1, 2026 |
| JonesTrading | JonesTrading | Hold Downgrades $39 → $27 | Hold | Downgrades | $39 → $27 | n/a | Apr 29, 2026 |
| Leerink Partners | Leerink Partners | Hold Downgrades $27 | Hold | Downgrades | $27 | n/a | Apr 29, 2026 |
Financial Forecast
Revenue This Year
213.46M
Increased by 189.96%
Revenue Next Year
348.38M
from 213.46M
Increased by 63.21%
EPS This Year
-0.88
from -2.03
EPS Next Year
1.55
from -0.88
EPS and Forward PE are based on non-GAAP adjusted numbers.